Home › Research › Treatments
Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries
Frank F. Zhou, Utibe R. Essien, Jeffrey M. Souza, Catherine A. Sarkisian, Cheryl L. Damberg, Bruce E. Landon, John N. Mafi. JAMA Network Open, 2025-05-15
Topic: Risk, prevention and care in population studies
Plain-language summary
This cross-sectional study examines lecanemeb update among Medicare fee-for-service beneficiaries with Alzheimer disease or mild cognitive impairment and evaluates whether there are disparities among potentially eligible patients.
What this study adds
Evidence grade: Low
This is a cross-sectional study. This cross-sectional study looked at how many US Medicare beneficiaries with Alzheimer disease or mild cognitive impairment received lecanemab and whether some groups were less likely to get it. It reports on uptake patterns only, not on whether the drug helped those patients.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhou, F. F., Essien, U. R., Souza, J. M., Sarkisian, C. A., Damberg, C. L., Landon, B. E., et al. (2025). Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.11711
Vancouver
Zhou FF, Essien UR, Souza JM, Sarkisian CA, Damberg CL, Landon BE, et al. Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.11711. PMID: 40372759.
BibTeX
@article{zhou2025-40372759,
author = {Zhou, Frank F. and Essien, Utibe R. and Souza, Jeffrey M. and Sarkisian, Catherine A. and Damberg, Cheryl L. and Landon, Bruce E. and Mafi, John N.},
title = {{Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries}},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.11711},
pmid = {40372759},
url = {https://doi.org/10.1001/jamanetworkopen.2025.11711}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- This cross-sectional study examines lecanemeb update among Medicare fee-for-service beneficiaries with Alzheimer disease or mild cognitive impairment and evaluates whether there are disparities among potentially eligible patients.
Why it matters
This cross-sectional study looked at how many US Medicare beneficiaries with Alzheimer disease or mild cognitive impairment received lecanemab and whether some groups were less likely to get it. It reports on uptake patterns only, not on whether the drug helped those patients.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 50/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Network Open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author John N. Mafi: h-index 20 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40372759) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2025.11711
- PubMed: 40372759
- Original source →
- Free full text: JAMA Network Open →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.